Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
01/12/2025 13:39
Dec 1 (Reuters) - Lotus Pharmaceutical Co Ltd 1795.TW: LENZ THERAPEUTICS ANNOUNCES MFDS SUBMISSION OF NEW DRUG APPLICATION FOR LNZ100 (VIZZ™) IN SOUTH KOREA FOR THE TREATMENT OF PRESBYOPIA Source text: ID:nGNX5V5qyL Further company coverage: 1795.TW ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lotus Pharmaceutical
See all newsMedia: PTT is said to consider options for Taiwan-listed Lotus Pharma - Bloomberg News
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea